adrenocorticotropin-zinc and Pheochromocytoma

adrenocorticotropin-zinc has been researched along with Pheochromocytoma* in 2 studies

Reviews

1 review(s) available for adrenocorticotropin-zinc and Pheochromocytoma

ArticleYear
[Subclinical adrenal diseases: silent pheochromocytoma and subclinical Addison's disease].
    Annales d'endocrinologie, 2012, Volume: 73 Suppl 1

    The silent pheochromocytoma, a hidden form of pheochromocytoma, exposes the patient to an increased risk of mortality if the diagnosis is not established on time. Biological diagnosis of pheochromocytoma can be difficult. Catecholamine secretion is dependent on tumor size and a large number of physiological, pharmacological, lifestyle modifications and sampling conditions influence the measurement of urinary and plasma metanephrines. The prevalence of pheochromocytoma is 2% among adrenal incidentaloma smaller than 3 cm (2/3 of tumors). Recent studies suggest the almost zero risk of pheochromocytoma among these tumors if they are hypodense (<10 housefield units) on adrenal tomography. Addison's disease is a pathology affecting about 1 in 8000. Immunopathology is still unknown, but some elements advocated the hypothesis of a predominant cell-mediated immunity in particular Interferon-gamma production by CD4 T lymphocytes in the presence of an epitope from the 21-hydroxylase, as well as IgG1 subtype produced by activated B lymphocytes, autoantibodies do appear to be a simple marker of the disease. Subclinical Addison's disease is defined by the presence of anti-21-hydroxylase autoantibodies, without clinical symptoms. It evolves faster to the clinical phase in young subjects, male, having high levels of autoantibodies and with an initially impaired adrenal function. Dosage of ACTH, plasma renin active, and basal cortisol and after Synacthen allow to discriminate the subjects with low or high risk of evolution and establish an appropriate monitoring.

    Topics: Addison Disease; Adrenal Gland Neoplasms; Adrenal Glands; Adrenocorticotropic Hormone; Autoantibodies; CD4-Positive T-Lymphocytes; Cosyntropin; Humans; Hydrocortisone; Immunity, Cellular; Interferon-gamma; Male; Metanephrine; Pheochromocytoma; Renin; Steroid 21-Hydroxylase

2012

Other Studies

1 other study(ies) available for adrenocorticotropin-zinc and Pheochromocytoma

ArticleYear
Synacthen Stimulation Test Following Unilateral Adrenalectomy Needs to Be Interpreted With Caution.
    Frontiers in endocrinology, 2021, Volume: 12

    Cortisol levels in response to stress are highly variable. Baseline and stimulated cortisol levels are commonly used to determine adrenal function following unilateral adrenalectomy. We report the results of synacthen stimulation testing following unilateral adrenalectomy in a tertiary referral center.. Data were collected retrospectively for 36 patients who underwent synacthen stimulation testing one day post unilateral adrenalectomy. None of the patients had clinical signs of hypercortisolism preoperatively. No patient received pre- or intraoperative steroids. Patients with overt Cushing's syndrome were excluded.. The median age was 58 (31-79) years. Preoperatively, 16 (44%) patients had a diagnosis of pheochromocytoma, 12 (33%) patients had primary aldosteronism and 8 (22%) patients had non-functioning adenomas with indeterminate/atypical imaging characteristics necessitating surgery. Preoperative overnight dexamethasone suppression test results revealed that 6 of 29 patients failed to suppress cortisol to <50 nmol/L. Twenty (56%) patients achieved a stimulated cortisol ≥450 nmol/L at 30 minutes and 28 (78%) at 60 minutes. None of the patients developed clinical adrenal insufficiency necessitating steroid replacement.. Synacthen stimulation testing following unilateral adrenalectomy using standard stimulated cortisol cut-off values would wrongly label many patients adrenally insufficient and may lead to inappropriate prescriptions of steroids to patients who do not need them.

    Topics: Adenoma; Adrenal Gland Neoplasms; Adrenal Insufficiency; Adrenalectomy; Adult; Aged; Cosyntropin; Cushing Syndrome; Dexamethasone; Endocrinology; Female; Humans; Hydrocortisone; Hyperaldosteronism; Male; Middle Aged; Pheochromocytoma; Postoperative Period; Retrospective Studies

2021